HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Breast-Conserving Therapy Bests Mastectomy After Preoperative Systemic Therapy in HER2+ Breast Cancer

April 9th 2024

Following preoperative systemic therapy, breast-conserving therapy led to superior OS vs mastectomy in HER2-positive breast cancer.

Dr Nanda on Neoadjuvant Treatment in HER2+ Breast Cancer

April 4th 2024

Rita Nanda, MD, discusses the future of neoadjuvant treatment for patients with HER2-positive breast cancer.

Tiwari Highlights Updates in HER2+ and HER2-Low Breast Cancer

April 4th 2024

Shruti Tiwari, MD, discusses treatment advances in HER2-positive and HER2-low breast cancer and looks ahead to the future of the space.

Tripathy Outlines Where the HER2+ Early-Stage Breast Cancer Landscape Stands

April 3rd 2024

Debu Tripathy, MD, discusses the current treatment paradigm of HER2-positive breast cancer and highlights unmet needs that remain.

Clinical Benefits With Neratinib in HER2+ Early Breast Cancer

March 25th 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss the clinical benefits reported with neratinib for the treatment of patients with HER2-positive early breast cancer.

Ongoing Research Efforts in HER2+ Early Breast Cancer

March 25th 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss ongoing research efforts in HER2-positive early breast cancer.

Dr Mahtani on the Expansion of Targeted Therapies in HER2+ Breast Cancer

March 22nd 2024

Reshma L. Mahtani, DO, discusses how the expansion of HER2-targeted agents has impacted the management of HER2-positive breast cancer.

AE Management With Neratinib in HER2+ Early Breast Cancer

March 18th 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss optimal management for adverse effects related to neratinib for patients with HER2-positive early breast cancer.

Unmet Needs in HER2+ Early Breast Cancer

March 18th 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss unmet needs in the treatment of patients with HER2-positive early breast cancer.

Evolving and Current Standards of Care for HER2+ Early Breast Cancer

March 12th 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss how standard-of-care treatment has evolved for patients with HER2-positive early breast cancer.

Prognosis and Survival Outcomes for HER2+ Early Breast Cancer

March 12th 2024

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss clinical updates to the management of patients with HER2-positive early breast cancer.

HER2-Directed Therapies Continue to Shape Improved Breast Cancer Outcomes

March 10th 2024

Debu Tripathy, MD, provides insights on the management of HER2-positive breast cancer, including the evolving role of trastuzumab in this population.

T-DXd Has Intracranial Activity in Meta-Analysis of HER2+ Breast Cancer Brain Metastases

March 8th 2024

Trastuzumab deruxtecan has significant intracranial activity in patients with HER2-positive breast cancer brain metastases, regardless of subgroup.

T-DXd Fails to Receive Recommendation From NICE for HER2-Low Breast Cancer Treatment

March 6th 2024

The UK’s NICE has announced that it will not recommend the use of trastuzumab deruxtecan for the treatment of patients with HER2-low breast cancer.

Sammons Spotlights Approaches Under Exploration for HER2+ Breast Cancer and Brain Metastases

February 19th 2024

Sarah Sammons, MD, discusses research efforts in breast cancer focused on HER2-directed therapeutic approaches with central nervous system activity.

Dr McAndrew on the HER2CLIMB-02 Trial in HER2+ Breast Cancer

February 15th 2024

Nicholas P. McAndrew, MD, MSCE, discusses the phase 3 HER2CLIMB-02 trial of tucatinib plus trastuzumab emtansine in HER2-positive early breast cancer.

Real-World Analysis Sheds Light on Brain Metastases Incidence in HER2+ Breast Cancer

February 15th 2024

Sarah Sammons, MD, discusses what is known about the incidence of brain metastases in patients with breast cancer.

The Ongoing Investigation of GLSI-100 Continues in the Flamingo-01 Study for HER2/Neu+ Breast Cancer

February 14th 2024

The ongoing Flamingo-01 trial continues to investigate GLSI-100 in HER2/neu-positive breast cancer following various holds.

Dr Sammons on the Investigation of Brain Metastases in HER2+ Breast Cancer

February 13th 2024

Sarah Sammons, MD, discusses the rationale for examining brain metastases in HER2-positive breast cancer, highlighting the implications of recent data.

McAndrew Expands on the Evolving Treatment Armamentarium in HER2+ Breast Cancer

February 13th 2024

Nicholas P. McAndrew, MD, MSCE, discusses how updated clinical trial findings are shifting the treatment paradigm in HER2-positive metastatic breast cancer.